Use of PET and the radioligand [carbonyl-11C]WAY-100635 in psychotropic drug development
- 1 July 2000
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 27 (5), 515-521
- https://doi.org/10.1016/s0969-8051(00)00121-9
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography.Psychopharmacology, 1999
- In vivo intrinsic efficacy of the 5-HT1A receptor antagonists NAD-299, WAY-100,635 and (S)-(-)-UH-301 at rat brain monoamine receptorsEuropean Neuropsychopharmacology, 1999
- 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapineEuropean Journal of Pharmacology, 1997
- Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trialAmerican Journal of Psychiatry, 1997
- Effectiveness of Pindolol With Selected Antidepressant Drugs in the Treatment of Major DepressionJournal of Clinical Psychopharmacology, 1995
- PET in Neuropsychiatric Drug DevelopmentPublished by Springer Nature ,1995
- Interactions between 5-hydroxytryptamine receptor subtypes: Is a disturbed receptor balance contributing to the symptomatology of depression in humans?Pharmacology & Therapeutics, 1995
- The role of serotonin in depression and anxietyInternational Clinical Psychopharmacology, 1995
- Pindolol Induces a Rapid Improvement of Depressed Patients Treated With Serotonin Reuptake InhibitorsArchives of General Psychiatry, 1994
- Determination of Pindolol in Human Serum by HPLCJournal of Chromatographic Science, 1991